WHO panel gives nod to AstraZeneca Covid-19 vaccine, says it has 'tremendous potential'

The AstraZeneca Covid-19 vaccine (including Covishield) continues to have a positive benefit-risk profile, the panel said

The World Health Organization's vaccine safety panel said on Friday that data from AstraZeneca's Covid-19 shot do not point to an overall increase in clotting conditions but it would continue to monitor its effects.

"The AstraZeneca Covid-19 vaccine (including Covishield) continues to have a positive benefit-risk profile, with tremendous potential to prevent infections and reduce deaths across the world," the WHO's global advisory committee on vaccine safety said in a statement issued after its independent experts met on Tuesday and on Thursday to review data.